Lau Chin Shern, Oh May Lin Helen, Phua Soon Kieng, Liang Ya-Li, Aw Tar Choon
Department of Laboratory Medicine, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore.
Department of Infectious Diseases, Changi General Hospital, Singapore 529889, Singapore.
Vaccines (Basel). 2022 Oct 12;10(10):1703. doi: 10.3390/vaccines10101703.
Introduction: We tested the total spike antibody (S-Ab), IgG/IgM S-Ab, and neutralizing antibody (N-Ab) responses of COVID-19-naïve subjects from before their first BNT162b2 vaccination up to 210 days after boosting. Methods: We studied 136 COVID-19-naïve subjects who received three doses of the Pfizer mRNA vaccine (39 males, 97 females, mean age 43.8 ± 13.5 years) from January 2021 to May 2022. Serum was assessed for total S-Ab (Roche), IgG/M (Abbott), and N-Ab (Snibe). Results: Peak antibody levels were measured 20-30 days after each dose, with booster dosing eliciting significantly higher peak antibodies than the second dose: total S-Ab 2219 vs. 19,551 BAU/mL (difference 16,667 BAU/mL, p < 0.0001); IgG 2270 vs. 2932 BAU/mL (difference 660 BAU/mL, p = 0.04); and N-Ab 3.52 vs. 26.4 µg/mL (difference 21.4 µg/mL, p < 0.0001). Only IgM showed a lower peak post-booster antibody titer (COI 2.11 vs. 0.23, difference 1.63, 95% CI 1.05 to 2.38, p < 0.0001). By 180−210 days after the second or third vaccination, total S-Ab/IgG/N-Ab had decreased by 68.7/93.8/73.6% vs. 82.8/86.3/79.5%. The half-lives of IgG and N-Ab antibodies were longer after the third vaccination (IgG: 65 vs. 34 days, N-Ab: 99 vs. 78 days). Conclusion: Total S-Ab/IgG/N-Ab showed a greater increase post-booster, with IgG/N-Ab having a longer half-life.
我们检测了初次接种新冠疫苗的受试者从首次接种BNT162b2疫苗前直至加强免疫后210天的总刺突抗体（S-Ab）、IgG/IgM S-Ab和中和抗体（N-Ab）反应。方法：我们研究了136名初次接种新冠疫苗的受试者，他们在2021年1月至2022年5月期间接种了三剂辉瑞mRNA疫苗（男性39名，女性97名，平均年龄43.8±13.5岁）。检测血清中的总S-Ab（罗氏公司）、IgG/M（雅培公司）和N-Ab（深圳新产业生物医学工程股份有限公司）。结果：每次接种后20 - 30天测量到抗体水平峰值，加强免疫诱导的峰值抗体显著高于第二剂：总S-Ab为2219 vs. 19551 BAU/mL（差值16667 BAU/mL，p < 0.000）；IgG为2270 vs. 2932 BAU/mL（差值660 BAU/mL，p = 0.04）；N-Ab为3.52 vs. 26.4 µg/mL（差值21.4 µg/mL，p < 0.000）。只有IgM在加强免疫后的抗体峰值滴度较低（COI 2.11 vs. 0.23，差值1.63，95%可信区间1.05至2.38，p < 0.000）。在第二次或第三次接种后180 - 210天，总S-Ab/IgG/N-Ab分别下降了68.7/93.8/73.6%，而之前下降了82.8/86.3/79.5%。第三次接种后IgG和N-Ab抗体的半衰期更长（IgG：65天 vs. 34天，N-Ab：99天 vs. 78天）。结论：加强免疫后总S-Ab/IgG/N-Ab有更大幅度的增加，且IgG/N-Ab具有更长的半衰期。
